Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06171906
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-15
First Post:
2023-11-06
Brief Title:
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor:
ShiCang Yu
Organization:
Southwest Hospital China
Study Overview
Official Title:
Clinical Study of MSCs for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Allogeneic hematopoietic stem cell transplantation allo-HSCT is an effective approach for treating both benign and malignant blood disorders It primarily involves high-dose chemotherapy to eliminate tumor cells within the patients body as well as to suppress the recipients hematopoiesis and immune function The transplantation replaces the recipients original hematopoietic stem cells HSCs with donor-derived HSCs thereby reconstructing the donors hematopoietic and immune functions to achieve disease cure
Poor graft function PGF following transplantation which refers to inadequate engraftment of the transplanted hematopoietic stem cells is one of the major factors limiting the effectiveness of allo-HSCT Mesenchymal stromal cells MSCs identified within the bone marrow stroma are a type of non-hematopoietic multipotent stem cells Several studies including previous research by our research team suggest that MSCs can improve the bone marrow hematopoietic microenvironment by secreting various cytokines This leads to the promotion of hematopoietic stem cell proliferation and differentiation enhancement of hematopoietic function and support for hematopoiesis as well as direct or indirect promotion of vascular regeneration in damaged tissues and organs
Therefore exploring the efficacy of umbilical cord-derived MSCs in treating poor graft function after allo-HSCT observing the recovery of blood parameters in patients with poor engraftment monitoring transplantation-related complications and immune reconstitution and conducting preliminary investigations into the underlying mechanisms can contribute to the exploration of new clinical techniques for the treatment of PGF following allo-HSCT
Poor graft function PGF following transplantation which refers to inadequate engraftment of the transplanted hematopoietic stem cells is one of the major factors limiting the effectiveness of allo-HSCT Mesenchymal stromal cells MSCs identified within the bone marrow stroma are a type of non-hematopoietic multipotent stem cells Several studies including previous research by our research team suggest that MSCs can improve the bone marrow hematopoietic microenvironment by secreting various cytokines This leads to the promotion of hematopoietic stem cell proliferation and differentiation enhancement of hematopoietic function and support for hematopoiesis as well as direct or indirect promotion of vascular regeneration in damaged tissues and organs
Therefore exploring the efficacy of umbilical cord-derived MSCs in treating poor graft function after allo-HSCT observing the recovery of blood parameters in patients with poor engraftment monitoring transplantation-related complications and immune reconstitution and conducting preliminary investigations into the underlying mechanisms can contribute to the exploration of new clinical techniques for the treatment of PGF following allo-HSCT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None